News
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
15 May 24
News, Price Target, Reiteration, Analyst Ratings
Syros Pharmaceuticals Q1 2024 GAAP EPS $(0.10) Beats $(0.86) Estimate, Cash (Incl Restricted Cash) $85.64M
14 May 24
Earnings, Earnings Beats, News
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
9 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 Apr 24
Movers
Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target
3 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Top 3 Health Care Stocks You'll Regret Missing This Month
2 Apr 24
Long Ideas, News, Small Cap, Pre-Market Outlook, Markets, Trading Ideas
Syros Pharmaceuticals Q4 EPS $(2.22) Misses $(1.14) Estimate, Sales $386.00K Miss $2.00M Estimate
27 Mar 24
Earnings, News
Earnings Scheduled For March 27, 2024
27 Mar 24
Earnings
Syros Pharmaceuticals's Earnings Outlook
26 Mar 24
Earnings
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
25 Mar 24
News
Press releases
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
18 Jun 24
Press Releases
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
13 Jun 24
Press Releases
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
14 May 24
Press Releases
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
9 Apr 24
Press Releases
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Press Releases
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
27 Mar 24
Press Releases
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
25 Mar 24
Press Releases